Listen Live
Donate
 on air
Schedule

KCRW

Read & Explore

  • News
  • Entertainment
  • Food
  • Culture
  • Events

Listen

  • Live Radio
  • Music
  • Podcasts
  • Full Schedule

Information

  • About
  • Careers
  • Help / FAQ
  • Newsletters
  • Contact

Support

  • Become a Member
  • Become a VIP
  • Ways to Give
  • Shop
  • Member Perks

Become a Member

Donate to KCRW to support this cultural hub for music discovery, in-depth journalism, community storytelling, and free events. You'll become a KCRW Member and get a year of exclusive benefits.

DonateGive Monthly

Copyright 2025 KCRW. All rights reserved.

Report a Bug|Privacy Policy|Terms of Service|
Cookie Policy
|FCC Public Files

Back to To the Point

To the Point

Drug-maker Mylan and its $300 "generic" EpiPen

Mylan might or might not have good news for people who need EpiPens. They provide quick injections to protect against potentially deadly anaphylactic shock from bee stings, peanut allergies and other sources. The drug company is still increasing the price of two EpiPens to $600 — while it also produces a so-called "generic" for $300.

  • rss
  • Share
By Warren Olney • Aug 29, 2016 • 1 min read

Mylan might or might not have good news for people who need EpiPens. They provide quick injections to protect against potentially deadly anaphylactic shock from bee stings, peanut allergies and other sources. The drug company is still increasing the price of two EpiPens to $600 — while it also produces a so-called "generic" for $300. Andrew Pollack covers the business and science of biotechnology for the New York Times.

  • https://images.ctfassets.net/2658fe8gbo8o/AvYox6VuEgcxpd20Xo9d3/769bca4fbf97bf022190f4813812c1e2/new-default.jpg?h=250

    Warren Olney

    former KCRW broadcaster

  • KCRW placeholder

    Sáša Woodruff

    Producer, 'To the Point'

  • KCRW placeholder

    Paul von Zielbauer

    Producer, 'To the Point'

  • https://images.ctfassets.net/2658fe8gbo8o/AvYox6VuEgcxpd20Xo9d3/769bca4fbf97bf022190f4813812c1e2/new-default.jpg?h=250

    Jenny Hamel

    KCRW

  • KCRW placeholder

    Andrew Pollack

    New York Times

    NewsNationalPolitics
Back to To the Point